Merus CEO Bill Lundberg
June 5, 2022 11:00 AM EDTUpdated June 6, 05:11 AM
R&D

#AS­CO22: Merus looks to beat El­e­va­tion to NRG1+ sum­mit as BLA fil­ing ap­proach­es

Kyle LaHucik

Senior Reporter

CHICA­GO — Merus wants to tack­le a rare ge­nom­ic fu­sion in on­col­o­gy that im­pacts about 5,000 new pa­tients in the US each year, and the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times